Table 6.
Immune response markers by vitamin A status at visit 1 (n = 57).
| Median (Q1-Q3) | p valuea | ||
|---|---|---|---|
| Immune response marker (MFI) | Insufficient (n = 8) | Sufficient (n = 49) | |
| EGF | 769.5 (225.3–902.0) | 217.0 (91.5–449.0) | 0.18 |
| Eotaxin | 322.8 (286.0–536.0) | 335.0 (228.0–432.0) | 0.67 |
| G-CSF | 57.0 (42.0–125.5) | 50.0 (31.0–81.0) | 0.68 |
| GM-CSF | 19.5 (19.0–29.0) | 21.0 (17.0–25.0) | 0.62 |
| IFNα2 | 15.0 (14.5–27.0) | 16.0 (13.0–21.0) | 0.88 |
| IFNγ | 53.5 (46.3–243.3) | 70.0 (34.0–113.0) | 0.86 |
| IL-10 | 122.5 (93.5–435.3) | 206.0 (112.5–598.0) | 0.16 |
| IL-12P40 | 37.5 (31.5–80.8) | 36.0 (27.0–52.0) | 0.48 |
| IL-12P70 | 16.8 (16.0–26.5) | 18.0 (15.0–27.0) | 0.27 |
| IL-13 | 67.5 (21.3–118.5) | 29.5 (17.0–50.0) | 0.11 |
| IL-15 | 41.8 (37.5–56.5) | 38.0 (31.0–55.0) | 0.58 |
| IL-17a | 34.0 (26.8–72.8) | 33.0 (26.0–75.0) | 0.52 |
| IL-1RA | 134.5 (71.3–253.3) | 61.0 (42.0–91.0) | 0.25 |
| IL-1α | 37.5 (31.8–45.8) | 35.0 (25.5–45.5) | 0.34 |
| IL-1β | 25.8 (22.0–34.5) | 22.0 (18.0–31.0) | 0.21 |
| IL-2 | 38.8 (32.5–46.0) | 34.0 (30.0–41.0) | 0.06 |
| IL-3 | 14.8 (14.0–18.0) | 13.0 (12.0–15.0) | 0.55 |
| IL-4 | 15.0 (13.0–26.0) | 14.0 (12.0–19.0) | 0.41 |
| IL-5 | 33.0 (20.0–42.0) | 21.0 (17.0–28.0) | 0.77 |
| IL-7 | 16.5 (15.5–48.8) | 19.0 (17.0–22.3) | 0.44 |
| IL-8 | 556.0 (300.8–1771.8) | 493.0 (278.0–728.0) | 0.76 |
| IP-10 | 15,113.5 (11,658.817,277.8) | 10,241.0 (6,623.015,304.0) | 0.76 |
| MCP-1 | 4,863.3 (3,387.5–9,795.3) | 5,647.5 (3,954.0–8,143.0) | 0.18 |
| MIP-1α | 117.5 (92.0–484.0) | 80.0 (59.0–112.0) | 0.03 |
| MIP-1β | 121.0 (56.5–220.8) | 80.0 (52.0–108.0) | 0.26 |
| TNFα | 213.3 (166.8–547.8) | 191.5 (150.5–256.0) | 0.20 |
| TNFβ | 94.0 (15.0–194.0) | 26.0 (15.0–67.0) | 0.15 |
| VEGF | 72.3 (52.8–173.0) | 50.0 (27.0–81.0) | 0.14 |
a
Multivariate linear regression adjusted for variables of age, sex, body mass index, province, and number of days following the onset of symptoms. All values in the regression model were natural log transformed